brexucabtagene autoleucel + Cyclophosphamide + Fludarabine
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Conditions
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Trial Timeline
Mar 7, 2016 → Nov 3, 2023
NCT ID
NCT02614066About brexucabtagene autoleucel + Cyclophosphamide + Fludarabine
brexucabtagene autoleucel + Cyclophosphamide + Fludarabine is a phase 1/2 stage product being developed by Gilead Sciences for Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02614066. Target conditions include Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia.
What happened to similar drugs?
0 of 10 similar drugs in Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia were approved
Approved (0) Terminated (1) Active (9)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
🔄Axicabtagene Ciloleucel + Platinum-containing Salvage Chemotherapy + Cyclophosphamide + FludarabineGilead SciencesPhase 3
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05537766 | Phase 2 | Terminated |
| NCT02614066 | Phase 1/2 | Completed |
Competing Products
20 competing products in Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia